Profile data is unavailable for this security.
About the company
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
- Revenue in USD (TTM)182.90k
- Net income in USD-13.03m
- Incorporated1997
- Employees11.00
- LocationAlterity Therapeutics LtdL 3 460 Bourke StMELBOURNE 3000AustraliaAUS
- Phone+61 39349-4906
- Fax+61 39822-7735
- Websitehttps://alteritytherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | 807.00k | -36.22m | 9.69m | 19.00 | -- | -- | -- | 12.01 | -63.82 | -63.82 | 0.3347 | -2.08 | 0.0122 | -- | 20.96 | 42,473.68 | -54.66 | -99.64 | -529.15 | -154.42 | 64.19 | 84.69 | -4,488.60 | -613.58 | -- | -- | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.37k | -13.94m | 9.84m | 12.00 | -- | 0.9173 | -- | 640.16 | -0.8458 | -0.8458 | 0.0008 | 0.3601 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 10.06m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Check Cap Ltd | 0.00 | -17.57m | 10.12m | 85.00 | -- | 0.4273 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Forte Biosciences Inc | 0.00 | -35.76m | 10.23m | 11.00 | -- | 0.602 | -- | -- | -22.03 | -22.03 | 0.00 | 11.64 | 0.00 | -- | -- | 0.00 | -124.89 | -72.06 | -170.91 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Jaguar Health Inc | 10.19m | -35.67m | 10.26m | 49.00 | -- | 0.5139 | -- | 1.01 | -41.34 | -41.34 | 6.62 | 2.48 | 0.1793 | 0.231 | 7.56 | 207,857.10 | -63.73 | -95.29 | -110.34 | -163.54 | 79.79 | 67.28 | -355.51 | -522.28 | 1.60 | -3.45 | 0.6333 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Virax Biolabs Group Ltd | 156.42k | -6.73m | 10.31m | 17.00 | -- | 1.21 | -- | 65.89 | -3.35 | -3.35 | 0.078 | 2.09 | 0.0205 | 3.51 | -- | 9,201.18 | -88.11 | -- | -91.88 | -- | 32.34 | -- | -4,308.35 | -- | 25.58 | -227.16 | 0.0418 | -- | 1,727.34 | -- | -23.38 | -- | -- | -- |
| Cell MedX Corp | 0.00 | -142.49k | 10.40m | 0.00 | -- | -- | -- | -- | -0.0021 | -0.0021 | 0.00 | -0.0028 | 0.00 | -- | -- | -- | -190.76 | -703.78 | -- | -- | -- | 84.03 | -- | -2,996.54 | -- | -4.35 | -- | -- | -100.00 | -- | 71.22 | -- | -- | -- |
| BioCardia Inc | 428.00k | -8.56m | 10.44m | 16.00 | -- | -- | -- | 24.38 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Enzon Pharmaceuticals Inc | 26.00k | 314.00k | 10.45m | 0.00 | 33.29 | 3.44 | -- | 401.90 | 0.0042 | 0.0042 | 0.0004 | 0.6277 | 0.0006 | -- | -- | -- | 3.39 | -0.8654 | 3.42 | -0.8851 | -- | -- | 6,111.54 | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 10.71m | 7.00 | -- | 4.27 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
| Alterity Therapeutics Ltd (ADR) | 182.90k | -13.03m | 10.88m | 11.00 | -- | 1.13 | -- | 59.46 | -2.13 | -2.13 | 0.0298 | 1.08 | 0.0115 | -- | 0.1307 | -- | -82.18 | -56.58 | -103.97 | -66.91 | -- | -- | -7,124.45 | -22,925.08 | -- | -- | 0.0114 | -- | 1,532.73 | 19.85 | -38.51 | -- | -4.01 | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 10.96m | 35.00 | -- | 0.5464 | -- | 1,096.23 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 11.04m | 12.00 | -- | 0.3337 | 4.09 | 0.6894 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| BioRestorative Therapies Inc | 174.10k | -8.00m | 11.49m | 11.00 | -- | 1.07 | -- | 65.98 | -1.22 | -1.22 | 0.029 | 1.56 | 0.0118 | -- | 6.65 | 15,827.27 | -54.42 | -192.11 | -68.75 | -329.32 | 47.45 | -- | -4,597.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
Data as of Sep 20 2024. Currency figures normalised to Alterity Therapeutics Ltd's reporting currency: US Dollar USD
0.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 48.33k | 0.55% |
| G1 Execution Services LLCas of 30 Jun 2024 | 23.31k | 0.26% |
| Twin Lakes Capital Management LLCas of 30 Jun 2024 | 5.93k | 0.07% |
| Providence Capital Advisors LLCas of 30 Jun 2024 | 200.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 81.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 50.00 | 0.00% |
| Sugarloaf Wealth Management LLCas of 30 Jun 2024 | 33.00 | 0.00% |
| Corecap Advisors LLCas of 30 Jun 2024 | 21.00 | 0.00% |
| Parametric Portfolio Associates LLCas of 30 Jun 2024 | 16.00 | 0.00% |
| Steward Partners Investment Advisory LLCas of 30 Jun 2024 | 6.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
